{"name":"Tetherex Pharmaceuticals Corporation","slug":"tetherex-pharmaceuticals-corporation","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0AJBVV95cUxPTWpXc3VzY3BHVkgtSzBYbE4zc2Rkenc4ZGNYUUZCenVDaEVXdGtYT1pEVWlsWjNmQnplMjNPQjdsaVRhOFdQUDN1eUdUTFQwZUxfOUIwa2NZdFJhZk5lQXZ0ZWpmQzkwY3lLb1dtSnQ2dGlWamJ2NTFhckFreFZNbmtyLXJ2T3lPeG0yMENQOFgxdEhobklMU2VHOVBLYUNyX01iVjRyOVdRZTM2WDB6MncwUk96aUM2TElVRmVDSWFpaTBIU1pXQWJWNUJCcXlsTHBwYmJXdUNDYVFPT09TeVBEaW1HZ0xqMG1MdlgxcF9YTVBRVEIyR3d3anRnTUptcGhsQktRazlzNk9HTmtTV2ZNMGNxOEw3QTR6QThFbDZUazBOekJlRlRmV3Z0b2h4ckdnYnlqMDFvU25rVVdRV1ZTaTFJVl9aZFdzOUEyM3M?oc=5","date":"2026-04-08","type":"pipeline","source":"Barchart.com","summary":"COPD Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Genentech, GlaxoSmithKline, Verona Pharma, Regeneron Pharma, Sanofi, MedImmune, EpiEndo Pharma, Tetherex Pharma, AstraZene","headline":"COPD Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Genentech, GlaxoSmithKline, Verona Pharma,","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxQblQ2eEttMko4Zk1MM0JDdjNXTURkeXRzLTdfLUVxVy1BQmZqZlNkbXd2cVViSDhiX2dybXE0UldoSHdEbjNTa2pwNF9xeWdFMWlSbzlZUEd6RGJ1SHM2OVVWUEpOeG1nbG9vdFlmalp1YzZNd29uT2R6eTZnZkJSbkJ3bmc0Zi1SdEE5OVA5TGlCc2VmSjM4bHV1enJFUFpFY2RsdmJ0dkJxVFJELXcyMDN1bUNaOU1KSHp2cjJKUEwySWxLYWZSWnM0WWxMZDVzSTdOOU15X3BTSUVNVFpEc2FYU1VfQVQ3RjhUcVpPUkprLU1haGkzN291M3JKMTNKNXloU1lZemtFaTh2R1J0VlNTZ0J0U25EQU91QTVsUGc?oc=5","date":"2026-04-07","type":"trial","source":"Business Upturn","summary":"Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight - Business Upturn","headline":"Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxOdmJtTy1PVXBHWGpWQ0dlM1otWU01LWJUZ0MtM0ZpRklNbW44d1BBdTR4WlRvdXViT1NTNW5VTlFKSXZoRTJSYkJadHVoTFh0R0lNQnV2VEtaUnptVmxYeWhkNU0tUldGRHdxSUh6YWd2ZWdWMzBrbVR6QVgwd0NlRV91MGY4aUdwR1lpMXJfcnJLQnp1eUF4UW5LaDBzcHdoZWxOdnlKeVE4M3ZpZ3k2czdmTjh3UUxnX2FXZ2dGNm5YTzJJVEtPUTNuZUxQLWRLWmtOTUpKMklFd29GU25xUVNWMTNGdkljeTJVdEJvdi1TTTBXWDFTWW0tRi1hNkFEbm56dUp5ZTV3Mm96bmFXZ1dFVWZ2Qk12UVpZR09B?oc=5","date":"2026-03-30","type":"trial","source":"Barchart.com","summary":"Chronic Obstructive Pulmonary Disease Clinical Trial Pipeline Appears Robust With 65+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com","headline":"Chronic Obstructive Pulmonary Disease Clinical Trial Pipeline Appears Robust With 65+ Key Pharma Companies Actively Work","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxOVE83cG41VGdaa2U0WnpzYUpxVDlBLUtCa05DaTlhOUVQQWtXaFRMbTlXTEFlbnNybGhiSWVOT01XZ25BN2YzRjhKdm83YVFUY3ZldjAyLVJQY1lwVXExSDl3VkNBSVY0SDI3MGxUcXpwajZOMjdoWDNkS3FLTDZWb050UC1LQXpJTjRCZ0dpZS0wQjNFcmVtN2k2enhHQldtNEZrMmItaVFrMXhQTGJBcWRoVFRDNHpYUklWOFk0UEZmeHl5MnZDUjQ5aWVDLWItQWNHb0FZZmszZFNrS2xSWGRXeXEyWGJzR0p4Z29EMUZkaUNfZlZRVG81bDVMS01yYWllakR1WmtBU3UzeHc?oc=5","date":"2025-10-21","type":"regulatory","source":"prnewswire.com","summary":"Emphysema Market Analysis Reveals Promising Growth Opportunities and Trends During the Forecast Period (2025-2034) | DelveInsight - prnewswire.com","headline":"Emphysema Market Analysis Reveals Promising Growth Opportunities and Trends During the Forecast Period (2025-2034) | Del","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxNc1BSX1Vlb2xnUFVQLVpybnV0NldIQjZ1MExoX0RvTnRiMk9SU2xxeHBMVFMtd2EwTGxMTFhLa1Z5SVE1blppZjl4akQ2TlM5TVJmUmhJZV9kNmNpb09aVktqTE5vNTYxTFU5ZFpfVEQwc1N3eGN1YmVfVzVNWndhdjV4Ql82OXkwcnM2Qk1oWnVCdnIxV19uT1NYYzJ2dmhuUUd4TVljV1dDc0tSUlpqY0lyQk5oS2QzbFhyTWtwYXdITlJsRlJ1WFVCUmgyYU5xM1NFRE1nbGhFV1QtdzZVaDk0WlhiY2pUaFJZdmlHUDdSZ2RVNlVxeDhxYjlsZmxVNWNoaVdLaGpqdUk?oc=5","date":"2024-11-20","type":"pipeline","source":"prnewswire.com","summary":"Chronic Refractory Cough Market Still Unexplored, with Pharma Companies Eyeing First-Mover Advantage in the US | DelveInsight - prnewswire.com","headline":"Chronic Refractory Cough Market Still Unexplored, with Pharma Companies Eyeing First-Mover Advantage in the US | DelveIn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxObHRZbW5qbUhROVktVlZwYWNoYjRlVEtjME5JVzlWRzFqdlhpLXljMk5BWmRqNXZXbmhpTFpHWlR1QmYtbm5WVEJwQ0xfaVFrTnhvRGNNMnkteHpmRGVvTTNYSnRjY3ZFa0QtLXVSX1Q3VFJLOUFtUTRQTTdhX3ZfWHJ5ZlIwRldIT1VpaER0ZndiekZ0akJvOFZPNFlfb21fU1pFQ0pwNVJqdXRNZVRKTDVCQnZJXy1VVWFTQlE0S0ZzVjRKdW1IVWx3WTdJSERaNzk3alM3Zk53Mmd5QWpRcEQzcEdJWVJ0RktSalJXUGRtZk9reGVTbnhkMmo0SlE?oc=5","date":"2024-08-07","type":"pipeline","source":"GlobeNewswire","summary":"Global Respiratory Drugs Market to Register Incremental Growth at a CAGR of ~6% by 2030 | DelveInsight - GlobeNewswire","headline":"Global Respiratory Drugs Market to Register Incremental Growth at a CAGR of ~6% by 2030 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxNX2JaNWhDc1c2YWVZSXpXMmZLYTFNZDhTVEFzTkdreDBmUk9Denp4T09RaFVZRUMtdnppNkQ0MlhrX09rZnBmS2ZTX1plODhRejIxWWdKLWVRclNOZ2dlVU90dEVIcXZ2UzRBcjROVlczeWluRlBIVVJoXy02Z3pwWmo0MDZHY1VUYmRHZEFzU3lOd2lPRWRJdTlkbjNCSV9udVJJY0ZfaGxuX190RkhWN2k3bS05eEozSi12ZHVIR2U3WlVFdnI1M2hjd3d5djQ?oc=5","date":"2018-04-22","type":"pipeline","source":"The Oklahoman","summary":"Team hopes to make Oklahoma City a pharmaceutical hub - The Oklahoman","headline":"Team hopes to make Oklahoma City a pharmaceutical hub","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPQzdLa0NyYTRfb0NnZEVMZmh6c3NabG5IaFlQdmpRWmdEZGl0TTZPdDljTFhQbFhvRTZRRTk5MlhiWmRrb2ctMklDb3dRT0Mta0dsUldka01fRENURTJtQm1hZC1TSmFpMUNvOGl1c1BLMnhvU3VUdEVxUkgycnU1NE11UHVoTC1uc3d0MlpIaXI1dw?oc=5","date":"2016-11-21","type":"deal","source":"Fierce Biotech","summary":"Novartis buys sickle cell player Selexys in $665M deal - Fierce Biotech","headline":"Novartis buys sickle cell player Selexys in $665M deal","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}